1. A pharmaceutical composition comprising
a) 0.5-50 mg of a GLP-1 agonist and
5 b) 20-800 mg, such as 50-500 mg, of a salt of N-(8-(2-
hydroxybenzoyl)amino)caprylic acid and c) 0.6-20 mg, such as 1-10 mg, lubricant, wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w/w %, such as at least 95 w/w % of the excipients of the composition. 10
2. The pharmaceutical composition according to claim 1, wherein the lubricant is
magnesium stearate or glyceryl dibehenate.
3. The pharmaceutical composition according to claim 1 or claim 2 consisting of:
15 a) a GLP-1 agonist,
b) a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and
c) at least one lubricant.
4. The pharmaceutical composition according to any of the previous claims, wherein said
20 salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid constitutes at least 90 w/w % of the
composition.
5. The pharmaceutical composition according to any of the previous claims, wherein the
compositions comprises 1-8 mg, such as 2-5 mg or such as 2-3 mg magnesium stearate
25 per 100 mg of said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid.
6. The pharmaceutical composition according to any of the previous claims wherein the
GLP-1 agonist is a GLP-1 peptide substituted with a fatty acid or a fatty diacid, such as a
GLP-1 agonist selected from the group consisting of: semaglutide, Ns26{2-[2-(2-{2-[2-(2-
30 {(S)-4-Carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butyrylamino}-
ethoxy)ethoxy]acetylamino}ethoxy)ethoxy]acetyl}, /\f57-{2-[2-(2-{2-[2-(2-{(S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butyrylamino}ethoxy)ethoxy]acetylamino}-ethoxy)ethoxy]-acetyl}-[Aib8,Arg34,Lys37]GLP-1(7-37)-peptide (GLP-1 agonist B) and N£27-[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butanoyl]-
35 amino] ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]-acetyl], N£36-[2-[2-[2-[[2-[2-[2-[[(4S)-4-

carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butanoyl]amino]ethoxy]ethoxy]acetyl]-amino]ethoxy]ethoxy]acetyl]-[Aib8,Glu22,Arg26,Lys27, Glu30,Arg34,Lys36]-GLP-1-(7-37)-peptidyl-Glu-Gly (GLP-1 agonist C).
5 7. The pharmaceutical composition according to any of the previous claims, wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC).
8. The pharmaceutical composition according to any of the previous claims, wherein a dose
10 unit comprises;
a) 0.5-20 mg of semaglutide,
b) 50-400 mg of SNAC and
c) 1-10 mg lubricant.
15 9. The pharmaceutical composition according to any of the previous claims, wherein a dose unit comprises;
a) 1-10 mg of semaglutide,
b) 50-300 mg of SNAC and
c) 1-10 mg magnesium stearate. 20
10. The pharmaceutical composition according to any of the previous claims 1-6, wherein a
dose unit comprises;
a) 0.5-20 mg of the GLP-1 agonist C,
b) 50-400 mg of SNAC and 25 c) 1-10 mg lubricant.
11. The pharmaceutical composition according to any of the previous claims 1-6, wherein a
dose unit comprises;
a) 1-10 mg of the GLP-1 agonist C,
30 b) 50-300 mg of SNAC and
c) 1-10 mg magnesium stearate.
12. The pharmaceutical composition according to any of the previous claims, wherein the
composition is a solid composition, such as a tablet for oral administration.
35

13. A pharmaceutical composition according to any of the previous claims for use in
medicine.
14. A pharmaceutical composition according to any of the previous claims for use in a
5 method of treatment of diabetes and/or obesity.
15. A method of treatment of a subject in need thereof, wherein the method comprises
administering a therapeutically active amount of a composition according to any of the
previous claims to said subject.